Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection. (3rd October 2021)
- Record Type:
- Journal Article
- Title:
- Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection. (3rd October 2021)
- Main Title:
- Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection
- Authors:
- Silva, Vanessa
Miranda, Carla
Bezerra, Mário
Antão, H. Sofia
Guimarães, João
Prada, Justina
Pires, Isabel
Maltez, Luís
Pereira, José E.
Capelo, José L.
Igrejas, Gilberto
Poeta, Patrícia - Abstract:
- Abstract : The presence of methicillin-resistant Staphylococcus aureus (MRSA) in bone infections difficults its treatment and is a sign of concern. The aim of this study was to evaluate in vitro activity of dalbavancin on pre-established adhered cells and 24 h old biofilms of MRSA strains isolated from a human bone infection. Thirty-three MRSA were isolated from osteomyelitis episodes. The antimicrobial susceptibility of these strains was assessed by the Kirby-Bauer disc diffusion method and the presence of resistance genes was screened by PCR. MRSA planktonic minimum inhibitory concentration and minimum bactericidal concentration were assessed. Minimum biofilm eradication concentration (MBEC) was performed by the microtiter biofilm formation assay. All 33 MRSA strains were classified as multidrug-resistant strains and susceptible to dalbavancin. Dalbavancin inhibited the growth of 54.6% and 52% of strains at the concentrations of 0.05 µg/mL and 1 µg/mL, respectively. The MBEC values up to 0.4 µg/mL demonstrated that dalbavancin was active against most strains in pre-established adhered cells and 24 h old biofilms. The current results show that dalbavancin is active against adhered cells and biofilms in vitro, suggesting that this antimicrobial agent may be an option for the treatment of bone infections caused by MRSA.
- Is Part Of:
- Journal of chemotherapy. Volume 32:Number 7(2020)
- Journal:
- Journal of chemotherapy
- Issue:
- Volume 32:Number 7(2020)
- Issue Display:
- Volume 32, Issue 7 (2020)
- Year:
- 2020
- Volume:
- 32
- Issue:
- 7
- Issue Sort Value:
- 2020-0032-0007-0000
- Page Start:
- 469
- Page End:
- 475
- Publication Date:
- 2021-10-03
- Subjects:
- Dalbavancin -- biofilms -- MRSA -- MIC -- MBEC -- osteomyelitis
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
615.58 - Journal URLs:
- http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour%5Fid=57036 ↗
http://www.ingentaconnect.com/content/maney/joc ↗
http://www.jchemother.it ↗
http://www.jchemother.it/ ↗
http://www.maney.co.uk/index.php/journals/joc/ ↗
http://www.tandfonline.com/toc/yjoc20/current ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/1120009X.2021.1911518 ↗
- Languages:
- English
- ISSNs:
- 1120-009X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4957.390000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21366.xml